Aquestive Therapeutics, Inc.
AQST
$6.54
-$0.15-2.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -393.55% | -78.75% | -110.27% | -465.55% | 52.61% |
| Total Depreciation and Amortization | -31.71% | -32.85% | -65.59% | -39.77% | -29.07% |
| Total Amortization of Deferred Charges | 2.96% | 2.88% | 50.11% | 4,430.51% | 4,423.73% |
| Total Other Non-Cash Items | 49.02% | 1.30% | 22.05% | 103.12% | 96.47% |
| Change in Net Operating Assets | 110.99% | -143.75% | 580.36% | -236.26% | -170.85% |
| Cash from Operations | -12.96% | -125.35% | -31.30% | -406.18% | 11.39% |
| Capital Expenditure | -205.71% | -365.52% | 6.25% | 47.02% | 95.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -205.71% | -365.52% | 6.25% | 47.02% | 95.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -60.00% | -20.00% | 99.99% | -60.00% | 99.86% |
| Issuance of Common Stock | -- | -74.15% | -95.35% | -96.13% | -77.78% |
| Repurchase of Common Stock | -1,620.00% | 21.28% | -- | -- | -66.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.06% | -- | -- |
| Cash from Financing | -105.84% | -74.74% | -95.99% | -100.34% | -60.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.36% | -104.05% | -507.37% | -582.75% | -19.88% |